ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Cancer Antibody Drug Conjugates Market Research Report 2025
Published Date: August 2025
|
Report Code: QYRE-Auto-27H8462
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Cancer Antibody Drug Conjugates Market Insights and Forecast to 2028
BUY CHAPTERS

Global Cancer Antibody Drug Conjugates Market Research Report 2025

Code: QYRE-Auto-27H8462
Report
August 2025
Pages:99
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Novartis
Merck
Roche
AbbVie
UCB
Bristol–Myers Squibb
Stem CentRx
Biogen Idec
Nordic Nanovector
Millennium
Biotest
PDL BioPharma
Progenics Pharmaceuticals
Seattle Genetics
Viventia Biotechnologies
AbGenomics Corporation
Helix BioPharma

Cancer Antibody Drug Conjugates Market

The global market for Cancer Antibody Drug Conjugates was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
North American market for Cancer Antibody Drug Conjugates is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Cancer Antibody Drug Conjugates is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Cancer Antibody Drug Conjugates include Novartis, Merck, Roche, AbbVie, UCB, Bristol-Myers Squibb, Stem CentRx, Biogen Idec, Nordic Nanovector, Millennium, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Cancer Antibody Drug Conjugates, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cancer Antibody Drug Conjugates.
The Cancer Antibody Drug Conjugates market size, estimations, and forecasts are provided in terms of sales volume (K Dose) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Cancer Antibody Drug Conjugates market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Cancer Antibody Drug Conjugates manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Cancer Antibody Drug Conjugates Market Report

Report Metric Details
Report Name Cancer Antibody Drug Conjugates Market
Segment by Type
  • First & Second Generation ADCs
  • Third Generation ADCs
Segment by Application
  • Hospitals
  • Clinics
  • Others
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Novartis, Merck, Roche, AbbVie, UCB, Bristol-Myers Squibb, Stem CentRx, Biogen Idec, Nordic Nanovector, Millennium, Biotest AG, PDL BioPharma, Progenics Pharmaceuticals, Seattle Genetics, Viventia Biotechnologies, AbGenomics Corporation, Helix BioPharma
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Cancer Antibody Drug Conjugates manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Cancer Antibody Drug Conjugates in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the Cancer Antibody Drug Conjugates Market report?

Ans: The main players in the Cancer Antibody Drug Conjugates Market are Novartis, Merck, Roche, AbbVie, UCB, Bristol-Myers Squibb, Stem CentRx, Biogen Idec, Nordic Nanovector, Millennium, Biotest AG, PDL BioPharma, Progenics Pharmaceuticals, Seattle Genetics, Viventia Biotechnologies, AbGenomics Corporation, Helix BioPharma

What are the Application segmentation covered in the Cancer Antibody Drug Conjugates Market report?

Ans: The Applications covered in the Cancer Antibody Drug Conjugates Market report are Hospitals, Clinics, Others

What are the Type segmentation covered in the Cancer Antibody Drug Conjugates Market report?

Ans: The Types covered in the Cancer Antibody Drug Conjugates Market report are First & Second Generation ADCs, Third Generation ADCs

1 Cancer Antibody Drug Conjugates Market Overview
1.1 Product Definition
1.2 Cancer Antibody Drug Conjugates by Type
1.2.1 Global Cancer Antibody Drug Conjugates Market Value Comparison by Type (2024 VS 2031)
1.2.2 First & Second Generation ADCs
1.2.3 Third Generation ADCs
1.3 Cancer Antibody Drug Conjugates by Application
1.3.1 Global Cancer Antibody Drug Conjugates Market Value by Application (2024 VS 2031)
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Global Cancer Antibody Drug Conjugates Market Size Estimates and Forecasts
1.4.1 Global Cancer Antibody Drug Conjugates Revenue 2020-2031
1.4.2 Global Cancer Antibody Drug Conjugates Sales 2020-2031
1.4.3 Global Cancer Antibody Drug Conjugates Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Cancer Antibody Drug Conjugates Market Competition by Manufacturers
2.1 Global Cancer Antibody Drug Conjugates Sales Market Share by Manufacturers (2020-2025)
2.2 Global Cancer Antibody Drug Conjugates Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Cancer Antibody Drug Conjugates Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Cancer Antibody Drug Conjugates, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Cancer Antibody Drug Conjugates, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Cancer Antibody Drug Conjugates, Product Type & Application
2.7 Global Key Manufacturers of Cancer Antibody Drug Conjugates, Date of Enter into This Industry
2.8 Global Cancer Antibody Drug Conjugates Market Competitive Situation and Trends
2.8.1 Global Cancer Antibody Drug Conjugates Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Cancer Antibody Drug Conjugates Players Market Share by Revenue
2.8.3 Global Cancer Antibody Drug Conjugates Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Cancer Antibody Drug Conjugates Market Scenario by Region
3.1 Global Cancer Antibody Drug Conjugates Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Cancer Antibody Drug Conjugates Sales by Region: 2020-2031
3.2.1 Global Cancer Antibody Drug Conjugates Sales by Region: 2020-2025
3.2.2 Global Cancer Antibody Drug Conjugates Sales by Region: 2026-2031
3.3 Global Cancer Antibody Drug Conjugates Revenue by Region: 2020-2031
3.3.1 Global Cancer Antibody Drug Conjugates Revenue by Region: 2020-2025
3.3.2 Global Cancer Antibody Drug Conjugates Revenue by Region: 2026-2031
3.4 North America Cancer Antibody Drug Conjugates Market Facts & Figures by Country
3.4.1 North America Cancer Antibody Drug Conjugates Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Cancer Antibody Drug Conjugates Sales by Country (2020-2031)
3.4.3 North America Cancer Antibody Drug Conjugates Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Cancer Antibody Drug Conjugates Market Facts & Figures by Country
3.5.1 Europe Cancer Antibody Drug Conjugates Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Cancer Antibody Drug Conjugates Sales by Country (2020-2031)
3.5.3 Europe Cancer Antibody Drug Conjugates Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Cancer Antibody Drug Conjugates Market Facts & Figures by Region
3.6.1 Asia Pacific Cancer Antibody Drug Conjugates Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Cancer Antibody Drug Conjugates Sales by Region (2020-2031)
3.6.3 Asia Pacific Cancer Antibody Drug Conjugates Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Cancer Antibody Drug Conjugates Market Facts & Figures by Country
3.7.1 Latin America Cancer Antibody Drug Conjugates Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Cancer Antibody Drug Conjugates Sales by Country (2020-2031)
3.7.3 Latin America Cancer Antibody Drug Conjugates Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Cancer Antibody Drug Conjugates Market Facts & Figures by Country
3.8.1 Middle East and Africa Cancer Antibody Drug Conjugates Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Cancer Antibody Drug Conjugates Sales by Country (2020-2031)
3.8.3 Middle East and Africa Cancer Antibody Drug Conjugates Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Cancer Antibody Drug Conjugates Sales by Type (2020-2031)
4.1.1 Global Cancer Antibody Drug Conjugates Sales by Type (2020-2025)
4.1.2 Global Cancer Antibody Drug Conjugates Sales by Type (2026-2031)
4.1.3 Global Cancer Antibody Drug Conjugates Sales Market Share by Type (2020-2031)
4.2 Global Cancer Antibody Drug Conjugates Revenue by Type (2020-2031)
4.2.1 Global Cancer Antibody Drug Conjugates Revenue by Type (2020-2025)
4.2.2 Global Cancer Antibody Drug Conjugates Revenue by Type (2026-2031)
4.2.3 Global Cancer Antibody Drug Conjugates Revenue Market Share by Type (2020-2031)
4.3 Global Cancer Antibody Drug Conjugates Price by Type (2020-2031)
5 Segment by Application
5.1 Global Cancer Antibody Drug Conjugates Sales by Application (2020-2031)
5.1.1 Global Cancer Antibody Drug Conjugates Sales by Application (2020-2025)
5.1.2 Global Cancer Antibody Drug Conjugates Sales by Application (2026-2031)
5.1.3 Global Cancer Antibody Drug Conjugates Sales Market Share by Application (2020-2031)
5.2 Global Cancer Antibody Drug Conjugates Revenue by Application (2020-2031)
5.2.1 Global Cancer Antibody Drug Conjugates Revenue by Application (2020-2025)
5.2.2 Global Cancer Antibody Drug Conjugates Revenue by Application (2026-2031)
5.2.3 Global Cancer Antibody Drug Conjugates Revenue Market Share by Application (2020-2031)
5.3 Global Cancer Antibody Drug Conjugates Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Novartis
6.1.1 Novartis Company Information
6.1.2 Novartis Description and Business Overview
6.1.3 Novartis Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Novartis Cancer Antibody Drug Conjugates Product Portfolio
6.1.5 Novartis Recent Developments/Updates
6.2 Merck
6.2.1 Merck Company Information
6.2.2 Merck Description and Business Overview
6.2.3 Merck Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Merck Cancer Antibody Drug Conjugates Product Portfolio
6.2.5 Merck Recent Developments/Updates
6.3 Roche
6.3.1 Roche Company Information
6.3.2 Roche Description and Business Overview
6.3.3 Roche Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Roche Cancer Antibody Drug Conjugates Product Portfolio
6.3.5 Roche Recent Developments/Updates
6.4 AbbVie
6.4.1 AbbVie Company Information
6.4.2 AbbVie Description and Business Overview
6.4.3 AbbVie Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2020-2025)
6.4.4 AbbVie Cancer Antibody Drug Conjugates Product Portfolio
6.4.5 AbbVie Recent Developments/Updates
6.5 UCB
6.5.1 UCB Company Information
6.5.2 UCB Description and Business Overview
6.5.3 UCB Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2020-2025)
6.5.4 UCB Cancer Antibody Drug Conjugates Product Portfolio
6.5.5 UCB Recent Developments/Updates
6.6 Bristol-Myers Squibb
6.6.1 Bristol-Myers Squibb Company Information
6.6.2 Bristol-Myers Squibb Description and Business Overview
6.6.3 Bristol-Myers Squibb Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Bristol-Myers Squibb Cancer Antibody Drug Conjugates Product Portfolio
6.6.5 Bristol-Myers Squibb Recent Developments/Updates
6.7 Stem CentRx
6.7.1 Stem CentRx Company Information
6.7.2 Stem CentRx Description and Business Overview
6.7.3 Stem CentRx Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Stem CentRx Cancer Antibody Drug Conjugates Product Portfolio
6.7.5 Stem CentRx Recent Developments/Updates
6.8 Biogen Idec
6.8.1 Biogen Idec Company Information
6.8.2 Biogen Idec Description and Business Overview
6.8.3 Biogen Idec Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Biogen Idec Cancer Antibody Drug Conjugates Product Portfolio
6.8.5 Biogen Idec Recent Developments/Updates
6.9 Nordic Nanovector
6.9.1 Nordic Nanovector Company Information
6.9.2 Nordic Nanovector Description and Business Overview
6.9.3 Nordic Nanovector Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Nordic Nanovector Cancer Antibody Drug Conjugates Product Portfolio
6.9.5 Nordic Nanovector Recent Developments/Updates
6.10 Millennium
6.10.1 Millennium Company Information
6.10.2 Millennium Description and Business Overview
6.10.3 Millennium Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Millennium Cancer Antibody Drug Conjugates Product Portfolio
6.10.5 Millennium Recent Developments/Updates
6.11 Biotest AG
6.11.1 Biotest AG Company Information
6.11.2 Biotest AG Description and Business Overview
6.11.3 Biotest AG Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Biotest AG Cancer Antibody Drug Conjugates Product Portfolio
6.11.5 Biotest AG Recent Developments/Updates
6.12 PDL BioPharma
6.12.1 PDL BioPharma Company Information
6.12.2 PDL BioPharma Description and Business Overview
6.12.3 PDL BioPharma Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2020-2025)
6.12.4 PDL BioPharma Cancer Antibody Drug Conjugates Product Portfolio
6.12.5 PDL BioPharma Recent Developments/Updates
6.13 Progenics Pharmaceuticals
6.13.1 Progenics Pharmaceuticals Company Information
6.13.2 Progenics Pharmaceuticals Description and Business Overview
6.13.3 Progenics Pharmaceuticals Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Progenics Pharmaceuticals Cancer Antibody Drug Conjugates Product Portfolio
6.13.5 Progenics Pharmaceuticals Recent Developments/Updates
6.14 Seattle Genetics
6.14.1 Seattle Genetics Company Information
6.14.2 Seattle Genetics Description and Business Overview
6.14.3 Seattle Genetics Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2020-2025)
6.14.4 Seattle Genetics Cancer Antibody Drug Conjugates Product Portfolio
6.14.5 Seattle Genetics Recent Developments/Updates
6.15 Viventia Biotechnologies
6.15.1 Viventia Biotechnologies Company Information
6.15.2 Viventia Biotechnologies Description and Business Overview
6.15.3 Viventia Biotechnologies Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2020-2025)
6.15.4 Viventia Biotechnologies Cancer Antibody Drug Conjugates Product Portfolio
6.15.5 Viventia Biotechnologies Recent Developments/Updates
6.16 AbGenomics Corporation
6.16.1 AbGenomics Corporation Company Information
6.16.2 AbGenomics Corporation Description and Business Overview
6.16.3 AbGenomics Corporation Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2020-2025)
6.16.4 AbGenomics Corporation Cancer Antibody Drug Conjugates Product Portfolio
6.16.5 AbGenomics Corporation Recent Developments/Updates
6.17 Helix BioPharma
6.17.1 Helix BioPharma Company Information
6.17.2 Helix BioPharma Description and Business Overview
6.17.3 Helix BioPharma Cancer Antibody Drug Conjugates Sales, Revenue and Gross Margin (2020-2025)
6.17.4 Helix BioPharma Cancer Antibody Drug Conjugates Product Portfolio
6.17.5 Helix BioPharma Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Cancer Antibody Drug Conjugates Industry Chain Analysis
7.2 Cancer Antibody Drug Conjugates Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Cancer Antibody Drug Conjugates Production Mode & Process Analysis
7.4 Cancer Antibody Drug Conjugates Sales and Marketing
7.4.1 Cancer Antibody Drug Conjugates Sales Channels
7.4.2 Cancer Antibody Drug Conjugates Distributors
7.5 Cancer Antibody Drug Conjugates Customer Analysis
8 Cancer Antibody Drug Conjugates Market Dynamics
8.1 Cancer Antibody Drug Conjugates Industry Trends
8.2 Cancer Antibody Drug Conjugates Market Drivers
8.3 Cancer Antibody Drug Conjugates Market Challenges
8.4 Cancer Antibody Drug Conjugates Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Novartis
Merck
Roche
AbbVie
UCB
Bristol–Myers Squibb
Stem CentRx
Biogen Idec
Nordic Nanovector
Millennium
Biotest
PDL BioPharma
Progenics Pharmaceuticals
Seattle Genetics
Viventia Biotechnologies
AbGenomics Corporation
Helix BioPharma
List of Tables
 Table 1. Global Cancer Antibody Drug Conjugates Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Cancer Antibody Drug Conjugates Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Cancer Antibody Drug Conjugates Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Cancer Antibody Drug Conjugates Sales (K Dose) of Key Manufacturers (2020-2025)
 Table 5. Global Cancer Antibody Drug Conjugates Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Cancer Antibody Drug Conjugates Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Cancer Antibody Drug Conjugates Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Cancer Antibody Drug Conjugates Average Price (USD/Dose) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Cancer Antibody Drug Conjugates, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Cancer Antibody Drug Conjugates, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Cancer Antibody Drug Conjugates, Product Type & Application
 Table 12. Global Key Manufacturers of Cancer Antibody Drug Conjugates, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Cancer Antibody Drug Conjugates by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Antibody Drug Conjugates as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Cancer Antibody Drug Conjugates Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Cancer Antibody Drug Conjugates Sales by Region (2020-2025) & (K Dose)
 Table 18. Global Cancer Antibody Drug Conjugates Sales Market Share by Region (2020-2025)
 Table 19. Global Cancer Antibody Drug Conjugates Sales by Region (2026-2031) & (K Dose)
 Table 20. Global Cancer Antibody Drug Conjugates Sales Market Share by Region (2026-2031)
 Table 21. Global Cancer Antibody Drug Conjugates Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Cancer Antibody Drug Conjugates Revenue Market Share by Region (2020-2025)
 Table 23. Global Cancer Antibody Drug Conjugates Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Cancer Antibody Drug Conjugates Revenue Market Share by Region (2026-2031)
 Table 25. North America Cancer Antibody Drug Conjugates Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Cancer Antibody Drug Conjugates Sales by Country (2020-2025) & (K Dose)
 Table 27. North America Cancer Antibody Drug Conjugates Sales by Country (2026-2031) & (K Dose)
 Table 28. North America Cancer Antibody Drug Conjugates Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Cancer Antibody Drug Conjugates Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Cancer Antibody Drug Conjugates Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Cancer Antibody Drug Conjugates Sales by Country (2020-2025) & (K Dose)
 Table 32. Europe Cancer Antibody Drug Conjugates Sales by Country (2026-2031) & (K Dose)
 Table 33. Europe Cancer Antibody Drug Conjugates Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Cancer Antibody Drug Conjugates Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Cancer Antibody Drug Conjugates Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Cancer Antibody Drug Conjugates Sales by Region (2020-2025) & (K Dose)
 Table 37. Asia Pacific Cancer Antibody Drug Conjugates Sales by Region (2026-2031) & (K Dose)
 Table 38. Asia Pacific Cancer Antibody Drug Conjugates Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Cancer Antibody Drug Conjugates Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Cancer Antibody Drug Conjugates Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Cancer Antibody Drug Conjugates Sales by Country (2020-2025) & (K Dose)
 Table 42. Latin America Cancer Antibody Drug Conjugates Sales by Country (2026-2031) & (K Dose)
 Table 43. Latin America Cancer Antibody Drug Conjugates Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Cancer Antibody Drug Conjugates Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Cancer Antibody Drug Conjugates Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Cancer Antibody Drug Conjugates Sales by Country (2020-2025) & (K Dose)
 Table 47. Middle East and Africa Cancer Antibody Drug Conjugates Sales by Country (2026-2031) & (K Dose)
 Table 48. Middle East and Africa Cancer Antibody Drug Conjugates Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Cancer Antibody Drug Conjugates Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Cancer Antibody Drug Conjugates Sales (K Dose) by Type (2020-2025)
 Table 51. Global Cancer Antibody Drug Conjugates Sales (K Dose) by Type (2026-2031)
 Table 52. Global Cancer Antibody Drug Conjugates Sales Market Share by Type (2020-2025)
 Table 53. Global Cancer Antibody Drug Conjugates Sales Market Share by Type (2026-2031)
 Table 54. Global Cancer Antibody Drug Conjugates Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Cancer Antibody Drug Conjugates Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Cancer Antibody Drug Conjugates Revenue Market Share by Type (2020-2025)
 Table 57. Global Cancer Antibody Drug Conjugates Revenue Market Share by Type (2026-2031)
 Table 58. Global Cancer Antibody Drug Conjugates Price (USD/Dose) by Type (2020-2025)
 Table 59. Global Cancer Antibody Drug Conjugates Price (USD/Dose) by Type (2026-2031)
 Table 60. Global Cancer Antibody Drug Conjugates Sales (K Dose) by Application (2020-2025)
 Table 61. Global Cancer Antibody Drug Conjugates Sales (K Dose) by Application (2026-2031)
 Table 62. Global Cancer Antibody Drug Conjugates Sales Market Share by Application (2020-2025)
 Table 63. Global Cancer Antibody Drug Conjugates Sales Market Share by Application (2026-2031)
 Table 64. Global Cancer Antibody Drug Conjugates Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Cancer Antibody Drug Conjugates Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Cancer Antibody Drug Conjugates Revenue Market Share by Application (2020-2025)
 Table 67. Global Cancer Antibody Drug Conjugates Revenue Market Share by Application (2026-2031)
 Table 68. Global Cancer Antibody Drug Conjugates Price (USD/Dose) by Application (2020-2025)
 Table 69. Global Cancer Antibody Drug Conjugates Price (USD/Dose) by Application (2026-2031)
 Table 70. Novartis Company Information
 Table 71. Novartis Description and Business Overview
 Table 72. Novartis Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
 Table 73. Novartis Cancer Antibody Drug Conjugates Product
 Table 74. Novartis Recent Developments/Updates
 Table 75. Merck Company Information
 Table 76. Merck Description and Business Overview
 Table 77. Merck Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
 Table 78. Merck Cancer Antibody Drug Conjugates Product
 Table 79. Merck Recent Developments/Updates
 Table 80. Roche Company Information
 Table 81. Roche Description and Business Overview
 Table 82. Roche Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
 Table 83. Roche Cancer Antibody Drug Conjugates Product
 Table 84. Roche Recent Developments/Updates
 Table 85. AbbVie Company Information
 Table 86. AbbVie Description and Business Overview
 Table 87. AbbVie Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
 Table 88. AbbVie Cancer Antibody Drug Conjugates Product
 Table 89. AbbVie Recent Developments/Updates
 Table 90. UCB Company Information
 Table 91. UCB Description and Business Overview
 Table 92. UCB Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
 Table 93. UCB Cancer Antibody Drug Conjugates Product
 Table 94. UCB Recent Developments/Updates
 Table 95. Bristol-Myers Squibb Company Information
 Table 96. Bristol-Myers Squibb Description and Business Overview
 Table 97. Bristol-Myers Squibb Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
 Table 98. Bristol-Myers Squibb Cancer Antibody Drug Conjugates Product
 Table 99. Bristol-Myers Squibb Recent Developments/Updates
 Table 100. Stem CentRx Company Information
 Table 101. Stem CentRx Description and Business Overview
 Table 102. Stem CentRx Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
 Table 103. Stem CentRx Cancer Antibody Drug Conjugates Product
 Table 104. Stem CentRx Recent Developments/Updates
 Table 105. Biogen Idec Company Information
 Table 106. Biogen Idec Description and Business Overview
 Table 107. Biogen Idec Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
 Table 108. Biogen Idec Cancer Antibody Drug Conjugates Product
 Table 109. Biogen Idec Recent Developments/Updates
 Table 110. Nordic Nanovector Company Information
 Table 111. Nordic Nanovector Description and Business Overview
 Table 112. Nordic Nanovector Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
 Table 113. Nordic Nanovector Cancer Antibody Drug Conjugates Product
 Table 114. Nordic Nanovector Recent Developments/Updates
 Table 115. Millennium Company Information
 Table 116. Millennium Description and Business Overview
 Table 117. Millennium Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
 Table 118. Millennium Cancer Antibody Drug Conjugates Product
 Table 119. Millennium Recent Developments/Updates
 Table 120. Biotest AG Company Information
 Table 121. Biotest AG Description and Business Overview
 Table 122. Biotest AG Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
 Table 123. Biotest AG Cancer Antibody Drug Conjugates Product
 Table 124. Biotest AG Recent Developments/Updates
 Table 125. PDL BioPharma Company Information
 Table 126. PDL BioPharma Description and Business Overview
 Table 127. PDL BioPharma Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
 Table 128. PDL BioPharma Cancer Antibody Drug Conjugates Product
 Table 129. PDL BioPharma Recent Developments/Updates
 Table 130. Progenics Pharmaceuticals Company Information
 Table 131. Progenics Pharmaceuticals Description and Business Overview
 Table 132. Progenics Pharmaceuticals Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
 Table 133. Progenics Pharmaceuticals Cancer Antibody Drug Conjugates Product
 Table 134. Progenics Pharmaceuticals Recent Developments/Updates
 Table 135. Seattle Genetics Company Information
 Table 136. Seattle Genetics Description and Business Overview
 Table 137. Seattle Genetics Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
 Table 138. Seattle Genetics Cancer Antibody Drug Conjugates Product
 Table 139. Seattle Genetics Recent Developments/Updates
 Table 140. Viventia Biotechnologies Company Information
 Table 141. Viventia Biotechnologies Description and Business Overview
 Table 142. Viventia Biotechnologies Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
 Table 143. Viventia Biotechnologies Cancer Antibody Drug Conjugates Product
 Table 144. Viventia Biotechnologies Recent Developments/Updates
 Table 145. AbGenomics Corporation Company Information
 Table 146. AbGenomics Corporation Description and Business Overview
 Table 147. AbGenomics Corporation Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
 Table 148. AbGenomics Corporation Cancer Antibody Drug Conjugates Product
 Table 149. AbGenomics Corporation Recent Developments/Updates
 Table 150. Helix BioPharma Company Information
 Table 151. Helix BioPharma Description and Business Overview
 Table 152. Helix BioPharma Cancer Antibody Drug Conjugates Sales (K Dose), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2020-2025)
 Table 153. Helix BioPharma Cancer Antibody Drug Conjugates Product
 Table 154. Helix BioPharma Recent Developments/Updates
 Table 155. Key Raw Materials Lists
 Table 156. Raw Materials Key Suppliers Lists
 Table 157. Cancer Antibody Drug Conjugates Distributors List
 Table 158. Cancer Antibody Drug Conjugates Customers List
 Table 159. Cancer Antibody Drug Conjugates Market Trends
 Table 160. Cancer Antibody Drug Conjugates Market Drivers
 Table 161. Cancer Antibody Drug Conjugates Market Challenges
 Table 162. Cancer Antibody Drug Conjugates Market Restraints
 Table 163. Research Programs/Design for This Report
 Table 164. Key Data Information from Secondary Sources
 Table 165. Key Data Information from Primary Sources
 Table 166. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Cancer Antibody Drug Conjugates
 Figure 2. Global Cancer Antibody Drug Conjugates Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Cancer Antibody Drug Conjugates Market Share by Type: 2024 & 2031
 Figure 4. First & Second Generation ADCs Product Picture
 Figure 5. Third Generation ADCs Product Picture
 Figure 6. Global Cancer Antibody Drug Conjugates Market Value by Application (2020-2031) & (US$ Million)
 Figure 7. Global Cancer Antibody Drug Conjugates Market Share by Application: 2024 & 2031
 Figure 8. Hospitals
 Figure 9. Clinics
 Figure 10. Others
 Figure 11. Global Cancer Antibody Drug Conjugates Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 12. Global Cancer Antibody Drug Conjugates Market Size (2020-2031) & (US$ Million)
 Figure 13. Global Cancer Antibody Drug Conjugates Sales (2020-2031) & (K Dose)
 Figure 14. Global Cancer Antibody Drug Conjugates Average Price (USD/Dose) & (2020-2031)
 Figure 15. Cancer Antibody Drug Conjugates Report Years Considered
 Figure 16. Cancer Antibody Drug Conjugates Sales Share by Manufacturers in 2024
 Figure 17. Global Cancer Antibody Drug Conjugates Revenue Share by Manufacturers in 2024
 Figure 18. Global 5 and 10 Largest Cancer Antibody Drug Conjugates Players: Market Share by Revenue in Cancer Antibody Drug Conjugates in 2024
 Figure 19. Cancer Antibody Drug Conjugates Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 20. Global Cancer Antibody Drug Conjugates Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 21. North America Cancer Antibody Drug Conjugates Sales Market Share by Country (2020-2031)
 Figure 22. North America Cancer Antibody Drug Conjugates Revenue Market Share by Country (2020-2031)
 Figure 23. U.S. Cancer Antibody Drug Conjugates Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 24. Canada Cancer Antibody Drug Conjugates Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 25. Europe Cancer Antibody Drug Conjugates Sales Market Share by Country (2020-2031)
 Figure 26. Europe Cancer Antibody Drug Conjugates Revenue Market Share by Country (2020-2031)
 Figure 27. Germany Cancer Antibody Drug Conjugates Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 28. France Cancer Antibody Drug Conjugates Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. U.K. Cancer Antibody Drug Conjugates Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. Italy Cancer Antibody Drug Conjugates Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. Russia Cancer Antibody Drug Conjugates Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. Asia Pacific Cancer Antibody Drug Conjugates Sales Market Share by Region (2020-2031)
 Figure 33. Asia Pacific Cancer Antibody Drug Conjugates Revenue Market Share by Region (2020-2031)
 Figure 34. China Cancer Antibody Drug Conjugates Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. Japan Cancer Antibody Drug Conjugates Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. South Korea Cancer Antibody Drug Conjugates Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. India Cancer Antibody Drug Conjugates Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. Australia Cancer Antibody Drug Conjugates Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. Taiwan Cancer Antibody Drug Conjugates Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Indonesia Cancer Antibody Drug Conjugates Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Thailand Cancer Antibody Drug Conjugates Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Malaysia Cancer Antibody Drug Conjugates Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Philippines Cancer Antibody Drug Conjugates Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Latin America Cancer Antibody Drug Conjugates Sales Market Share by Country (2020-2031)
 Figure 45. Latin America Cancer Antibody Drug Conjugates Revenue Market Share by Country (2020-2031)
 Figure 46. Mexico Cancer Antibody Drug Conjugates Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Brazil Cancer Antibody Drug Conjugates Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Argentina Cancer Antibody Drug Conjugates Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 49. Middle East and Africa Cancer Antibody Drug Conjugates Sales Market Share by Country (2020-2031)
 Figure 50. Middle East and Africa Cancer Antibody Drug Conjugates Revenue Market Share by Country (2020-2031)
 Figure 51. Turkey Cancer Antibody Drug Conjugates Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. Saudi Arabia Cancer Antibody Drug Conjugates Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. U.A.E Cancer Antibody Drug Conjugates Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 54. Global Sales Market Share of Cancer Antibody Drug Conjugates by Type (2020-2031)
 Figure 55. Global Revenue Market Share of Cancer Antibody Drug Conjugates by Type (2020-2031)
 Figure 56. Global Cancer Antibody Drug Conjugates Price (USD/Dose) by Type (2020-2031)
 Figure 57. Global Sales Market Share of Cancer Antibody Drug Conjugates by Application (2020-2031)
 Figure 58. Global Revenue Market Share of Cancer Antibody Drug Conjugates by Application (2020-2031)
 Figure 59. Global Cancer Antibody Drug Conjugates Price (USD/Dose) by Application (2020-2031)
 Figure 60. Cancer Antibody Drug Conjugates Value Chain
 Figure 61. Channels of Distribution (Direct Vs Distribution)
 Figure 62. Bottom-up and Top-down Approaches for This Report
 Figure 63. Data Triangulation
 Figure 64. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Strategic Venue Partners

SIMILAR REPORTS

Global Antibody siRNA Drug Conjugates Market Research Report 2024
Global Antibodies in Oncology Market Research Report 2024
Global Antibody siRNA Conjugates Market Research Report 2024
Antibody Drug Conjugate Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Antibody Conjugation Kits Market Research Report 2024
Antibody Drug Conjugate Linker And Conjugation Technologies Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Antibody Drug Conjugate ADC Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Antibodies Market Research Report 2024
Antibody Drug Conjugation Service Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Monoclonal Antibodies Product Market Research Report 2024
Global ALK 1 Antibody Market Research Report 2024
Global Anti tumor Drug Market Research Report 2025
Global Anticancer Injection Market Research Report 2024
Global C Myc Antibody Market Research Report 2024
Global EGFR Antibody Market Research Report 2024
Global Next Generation Antibody Drug Market Research Report 2024
Global Antibody Testing Market Research Report 2024
Global Research Antibodies Market Research Report 2025
Global Monoclonal Antibody for Multiple Myeloma Market Research Report 2024
Global siRNA Conjugates Market Research Report 2024
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions